Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. (Q53269960)
Jump to navigation
Jump to search
scientific article published on 4 February 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. |
scientific article published on 4 February 2011 |
Statements
Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. (English)
Luca Bologna
Elisa Gotti
Massimiliano Manganini
Alessandro Rambaldi
Tamara Intermesoli
4 February 2011
186
6
3762-3769